FINWIRES · TerminalLIVE
FINWIRES

United Laboratories Unit Gets US FDA Nod for TUL321 Capsules

By

-- The United Laboratories International (HKG:3933) unit Zhuhai United Laboratories obtained approval for the new drug application of its TUL321 Capsules from the US Food and Drug Administration (FDA), according to a Tuesday Hong Kong bourse filing.

The FDA also accepted an application for the clinical trial registration of the drug.

The drug is intended to be used in the treatment of paroxysmal nocturnal hemoglobinuria (PNH), IgA nephropathy, age-related macular degeneration, multiple sclerosis, and myasthenia gravis.

Related Articles

Research

Needham Initiates Littelfuse at Buy With $450 Price Target

Littelfuse (LFUS) has an average rating of overweight and mean price target of $417.50, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$LFUS
Research

Baird Initiates Lyell Immunopharma at Outperform With $49 Price Target

Lyell Immunopharma (LYEL) has an average rating of buy and mean price target of $42.20, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$LYEL
Research

Jefferies Initiates Suncrete at Buy With $19 Price Target

$RMIX